Meeting
2015 ASCO Annual Meeting
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
Authors
Edward Jae-hoon Kim
UC Davis Comprehensive Cancer Center, Sacramento, CA
Edward Jae-hoon Kim , Thomas John Semrad , David R. Gandara , Jonathan Riess , Tianhong Li , Aiming Yu , Karen Matsukuma , Philip C. Mack , Karen Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cell Cycle and Checkpoints
Clinical Trial Registration Number
NCT01924260
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2526)
DOI
10.1200/jco.2015.33.15_suppl.2526
Abstract #
2526
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
First Author: Chia-Chi Lin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk